Australian medical cannabis company MMJ PhytoTech Limited has just sold its first marijuana pills. The bad news: They are only available in Europe.

The capsules were sold in August via a Swiss-based subsidiary, Satipharm. 10 milligrams of the medication will set you back 89 euros (A$139.95).

The pills are registered as a dietary supplement in Germany. Their active ingredient, Cannabidiol (CBD), is made from a special medical cannabis strain and they do not contain tetrahydrocannabinol (THC), the chemical that causes most of marijuana’s psychological effects when smoked.

Research has shown that CBD can help patients suffering from cancer, anxiety and epilepsy, the company said in a statement.

The pills are free of herbicides and pesticides, according to the company’s website. The operation has what it calls a “Farm to Pharma” approach to medical cannabis, producing capsules that are traceable from seedlings to pills.

“August was a month of ‘firsts’ for the Company … our first clinical study was approved, the first CBD Capsules were available on our new online direct sales platform and the Company’s first revenues were generated,” Andreas Gedeon, CEO and Managing Director of MMJ, said in a statement. “These achievements represent the progress we have made as a company in the implementation of our ‘Farm to Pharma’ strategy that will see our operations spanning the entire medical cannabis value chain.”

While medical marijuana remains by and large illegal in Australia, a survey from Palliative Care Australia in May found 67% of people would be fine with patients using a form of the drug to help with chronic pain and illness.

AusCann, an Australian cannabis producer, was given a license earlier this year to grow medicinal cannabis on Norfolk Island and export it to Canada.

(H/T Business Insider)

Have something to add to this story? Share it in the comments.